A phase II study of Osimertinib for patients with radiotherapy-naïve CNS metastasis of non-small cell lung cancer: treatment rationale and protocol design of the OCEAN study (LOGIK 1603/WJOG 9116L).

Abstract

BACKGROUND:

Patients with activating epidermal growth factor receptor (EGFR) mutations are highly responsive to EGFR-tyrosine kinase inhibitors (TKIs). However, it has been reported that approximately 15-30% of patients treated with EGFR-TKIs experience central nervous system (CNS) progression, and patients with EGFR mutations exhibit a higher incidence of brain metastasis than those without such mutations. The efficacy of osimertinib for treating CNS metastasis has been reported, but its efficacy for CNS metastasis in radiotherapy-naïve patients is unclear.

METHODS:

In the present prospective two-cohort phase II trial, 65 patients (T790M cohort, 40 patients; first-line cohort, 25 patients) with radiotherapy-naïve CNS metastasis of EGFR mutation-positive non-small cell lung cancer (NSCLC) will be included. Patients will be treated once-daily with osimertinib 80 mg. The primary endpoint is the response rate of brain metastasis as assessed using the PAREXEL criteria. Key secondary endpoints are progression-free survival and the response rate of brain metastasis as assessed using the RECIST criteria. We will exploratorily analyze the relationships of the blood concentration of osimertinib with its efficacy against brain metastasis of NSCLC and the accumulation of osimertinib in cerebrospinal fluid and evaluate tumor-derived DNA from plasma specimens for mutations in EGFR and other genes. Recruitment, which in October 2016, is ongoing.

DISCUSSION:

Although previous reports revealed the efficacy of osimertinib for CNS metastasis, these reports only involved subgroup analysis, and the efficacy of osimertinib for patients with previously untreated CNS metastasis remains unclear. The OCEAN study is the only trial of osimertinib for patients with untreated brain metastasis of NSCLC. This study should provide novel data about osimertinib. If the results of the OCEAN study are positive, then avoidance of radiotherapy will be recommended to patients harboring EGFR mutations and brain metastasis.

TRIAL REGISTRATION:

UMIN identifier: UMIN000024218 (date of initial registration: 29 September 2016). jRCT identifier: jRCTs071180017 (date of initial registration: 13 February 2019).

• Authors: Kazushige Wakuda, Hiroyuki Yamaguchi, Hirotsugu Kenmotsu, Minoru Fukuda, Masafumi Takeshita, Takayuki Suetsugu, Keisuke Kirita, Noriyuki Ebi, Osamu Hataji, Satoru Miura, Kenji Chibana, Isamu Okamoto, Kenichi Yoshimura, Kazuhiko Nakagawa, Nobuyuki Yamamoto, Kenji Sugio
• Journal: BMC cancer (BMC Cancer) Vol. 20 Issue 1 Pg. 370 (May 01 2020) ISSN: 1471-2407 [Electronic] England
• PMID: 32357848 (Publication Type: Clinical Trial Protocol, Journal Article)

Chemical References

• Acrylamides
• Aniline Compounds
• Antineoplastic Agents
• EGFR protein, human
• ErbB Receptors
• osimertinib

Topics

• Adult
• Aged
• Aged, 80 and over
• Female
• Humans
• Male
• Middle Aged
• Young Adult
• Acrylamides (therapeutic use)
• Aniline Compounds (therapeutic use)
• Antineoplastic Agents (therapeutic use)
• Carcinoma, Non-Small-Cell Lung (drug therapy, genetics, pathology)
• Central Nervous System Neoplasms (drug therapy, genetics, secondary)
• ErbB Receptors (genetics)
• Follow-Up Studies
• Lung Neoplasms (drug therapy, genetics, pathology)
• Mutation
• Prognosis
• Survival Rate
• Clinical Trials, Phase II as Topic
• Multicenter Studies as Topic